Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888968 | 0.89 | HPGD (0.49) | HTTHSD17B10LMNASMN1; SMN2KMT2A | |
| SCHEMBL7475639 | 0.88 | SMN1; SMN2 (0.56) | HTTHSD17B10LMNASMN1; SMN2KMT2A | |
| SCHEMBL6470099 | 0.88 | FAAH (0.66) | HTTLMNASMN1; SMN2KMT2ANR1H4 | |
| SCHEMBL480266 | 0.86 | MAPK1 (0.61) | HTTLMNASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL595191 | 0.86 | FAAH (0.51) | LMNASMN1; SMN2KMT2ANR1H4FAAH | |
| SCHEMBL10977234 | 0.85 | KMT2A (0.50) | HTTHSD17B10LMNAKMT2AFAAH | |
| SCHEMBL21768037 | 0.85 | THRB (0.51) | HTTLMNASMN1; SMN2KMT2ANR1H4 | |
| SCHEMBL7861824 | 0.85 | FAAH (0.50) | LMNASMN1; SMN2KMT2APLAUFAAH | |
| SCHEMBL29351023 | 0.85 | MEN1 (0.53) | HTTLMNASMN1; SMN2KMT2AFAAH | |
| SCHEMBL15746920 | 0.85 | MEN1 (0.53) | HTTLMNASMN1; SMN2KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | STANDARD LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | STANDARD LLC | 2019-08-08 | — | — | US | disclosed |
| CN-104860890-B | T790M mutant egfs R inhibitor and its application in antineoplastic is prepared | 上海泓博智源医药股份有限公司 | 2018-03-13 | — | — | CN | disclosed |
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | MEF2D, MYLK2, TNNT2 | HTT 2174/4885HSD17B10 1465/4885LMNA 774/4885 |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | MEF2D, MYLK2, MYOF | HTT 3339/4885HSD17B10 1062/4885LMNA 563/4885 |
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | HTT 4179/4885HSD17B10 2865/4885LMNA 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.